Factor (N = 73) | Very Important n (%) | Moderately Important n (%) | Somewhat Important n (%) | Less Important n (%) | Un- important n (%) |
---|---|---|---|---|---|
Patient/family preference | 15 (21) | 29 (40) | 22 (30) | 7 (9) | 0 |
aToxicity/side effects/tolerance of medications | 48 (65) | 21 (28) | 5 (7) | 0 | 0 |
Poor adherence to medications | 14 (19) | 34 (47) | 19 (26) | 6 (8) | 0 |
Younger age at diagnosis | 3 (4) | 8 (11) | 23 (32) | 31 (42) | 8 (11) |
bDuration of disease | 8 (12) | 35 (49) | 13 (18) | 13 (18) | 2 (3) |
Time maintained in inactive disease | 38 (52) | 29 (40) | 5 (7) | 1 (1) | 0 |
cAmount of time to achieve inactive disease | 24 (32) | 36 (49) | 12 (16) | 2 (3) | 0 |
cTotal number of DMARDs/ biologics used since diagnosis | 19 (26) | 29 (38) | 13 (18) | 11 (15) | 2 (3) |
Presence of JIA associated damage (joint or growth) | 15 (21) | 40 (56) | 12 (16) | 4 (6) | 2 (3) |
History of MAS | 36 (50) | 27 (37) | 8 (11) | 1 (1) | 1 (1) |
dHistory of previous cardiac or pulmonary involvement | 29 (41) | 24 (33) | 15 (21) | 3 (4) | 1 (1) |
History of previous ICU admission | 20 (27) | 34 (47) | 14 (19) | 3 (4) | 2 (3) |
Number of previous flares | 33 (45) | 25 (34) | 13 (18) | 2 (3) | 0 |
dPast failure of medication taper | 47 (65) | 20 (28) | 5 (7) | 0 | 0 |
Anticipated social or environmental changes | 1 (1) | 30 (42) | 27 (37) | 14 (19) | 1 (1) |